Human Predicted to work with:
Synthetic peptide within Human Jagged1 aa 1150-1250 (C terminal). The exact sequence is proprietary.
HepG2 and NIH:OVCAR-3 cell lysate. Bladder cancer tissue. HeLa cells.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
This product is a recombinant rabbit monoclonal antibody.
Use at an assay dependent concentration. PubMed: 24901044
Is unsuitable for ICC/IF.
Ligand for multiple Notch receptors and involved in the mediation of Notch signaling. May be involved in cell-fate decisions during hematopoiesis. Seems to be involved in early and late stages of mammalian cardiovascular development. Inhibits myoblast differentiation (By similarity). Enhances fibroblast growth factor-induced angiogenesis (in vitro).
Widely expressed in adult and fetal tissues. In cervix epithelium expressed in undifferentiated subcolumnar reserve cells and squamous metaplasia. Expression is up-regulated in cervical squamous cell carcinoma. Expressed in bone marrow cell line HS-27a which supports the long-term maintenance of immature progenitor cells.
Involvement in disease
Defects in JAG1 are the cause of Alagille syndrome type 1 (ALGS1) [MIM:118450]. Alagille syndrome is an autosomal dominant multisystem disorder defined clinically by hepatic bile duct paucity and cholestasis in association with cardiac, skeletal, and ophthalmologic manifestations. There are characteristic facial features and less frequent clinical involvement of the renal and vascular systems. Defects in JAG1 are a cause of tetralogy of Fallot (TOF) [MIM:187500]. TOF is a congenital heart anomaly which consists of pulmonary stenosis, ventricular septal defect, dextroposition of the aorta (aorta is on the right side instead of the left) and hypertrophy of the right ventricle. This condition results in a blue baby at birth due to inadequate oxygenation. Surgical correction is emergent.
Expressed in 32-52 days embryos in the distal cardiac outflow tract and pulmonary artery, major arteries, portal vein, optic vesicle, otocyst, branchial arches, metanephros, pancreas, mesocardium, around the major bronchial branches, and in the neural tube.
Immunohistochemical staining of paraffin embedded human kidney using purified ab109536 at a dilution of 1/300. A pre-diluted HRP polymer for rabbit IgG was used as the secondary and the sample was counter stained with hematoxylin.
Western blot - Anti-Jagged1 antibody [EPR4290] (ab109536)
Anti-Jagged1 antibody [EPR4290] (ab109536) at 1/1000 dilution (Purified) + HepG2 at 10 µg
Secondary HRP goat anti-rabbit (H+L) at 1/1000 dilution
Liu H et al. Jagged1 modulated tumor-associated macrophage differentiation predicts poor prognosis in patients with invasive micropapillary carcinoma of the breast. Medicine (Baltimore)96:e6663 (2017).
Read more (PubMed: 28422875) »
Sun P et al. SL2B aptamer and folic acid dual-targeting DNA nanostructures for synergic biological effect with chemotherapy to combat colorectal cancer. Int J Nanomedicine12:2657-2672 (2017).
Read more (PubMed: 28435250) »